Biotech Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Biovail Corp.
Biovail to promote Novartis' Lescol franchise in Canada
June 23rd, 2006
Biovail Corp. (BVF) announced that Biovail Pharmaceuticals Canada (BPC), the company's Canadian sales and marketing division, has entered into an agreement with Novartis Pharmaceuticals Canada, Inc., a wholly owned subsidiary of Novartis AG, to market and promote cholesterol medicines Lescol, fluvastatin sodium capsules, and once-daily Lescol XL, fluvastatin sodium extended-release tablets, to Canadian specialists and primary care physicians. Lescol and Lescol XL are indicated for the treatment of hypercholesterolemia and mixed hyperlipidemia in conjunction with a diet low in saturated fat and cholesterol. Lescol is also indicated for the secondary prevention of...
Source: Biotech Law Weekly (2006-06-23)
|
